IPI-504 (Phase 3) in Patients with Gastrointestinal Stromal Tumors

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib

• IRAS ID

  7629

• Contact name

  Ian Judson

• Contact email

  ian.judson@icr.ac.uk

• Sponsor organisation

  Infinity Pharmaceuticals, Inc.

• Eudract number

  2008-002396-28

• Clinicaltrials.gov Identifier

  NCT00688766

• Research summary

  Research Summary not published at request of researcher

• REC name

  London - South East Research Ethics Committee

• REC reference

  08/H1102/115

• Date of REC Opinion

  10 Feb 2009

• REC opinion

  Further Information Favourable Opinion